Sudoxicam

Research use only, not for human use.

Sudoxicam is a reversible antagonist of COX with anti-inflammatory, anti-edema, and antipyretic properties.

Sudoxicam is a reversible antagonist of COX with anti-inflammatory, anti-edema, and antipyretic properties.(In Vitro):Sudoxicam binds covalently to NADPH-dependent human liver microsomes. When glutathione (GSH) was added to the microsomal incubation, about half of the covalent binding of sudoxicam was blocked by glutathione.(In Vivo):Sudoxicam (0.1 mg/kg, p.o) significantly inhibits edema formation. In rats, Sudoxicam (1, 3.3 and 10 mg/kg; orally) effectively reduces plasma inflammation units, decreases the inflamed hind-paws swelling and restores toward normal the daily gain in body weight. Sudoxicam (3.3 mg/kg, i.p.) counteracts the pyrexia induced by the intraperitoneal injection of typhoid/paratyphoid vaccine and maintains body temperature. In the guinea pig, Sudoxicam inhibits the erythema caused by ultraviolet irradiation. The plasma half-life of Sudoxicam is 8, 13 and hours for monkey, rat and dog.

4-Hydroxy-2-methyl-N-2-thiazolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Chromatin/Epigenetic

COX

LXRα; LXRβ

——

——

34042-85-8

337.4

C13H11N3O4S2

>98% (HPLC)

——

CN1C(C(=O)Nc2nccs2)=C(O)c2ccccc2S1(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years